Retatrutide (LY3437943) is a novel triple agonist peptide targeting the GCGR, GIPR, and GLP-1R
Bleeding Risk The most common adverse reactions when combining GLP-1R agonists with traditional antithrombotic drugs such as aspirin, clopidogrel, or direct oral anticoagulants (DOACs) include gastrointestinal symptoms of nausea, vomiting, abdominal cramping, and increased bleeding risks
yellow arrows) are shown
Thus, the presence and state of glutathione is essential for the activity of many dehydrogenases (for example glutathione reductase)
It can be caused by alcohol consumption (alcoholic fatty liver disease) or non-alcoholic factors such as obesity, high cholesterol, and diabetes (non-alcoholic fatty liver disease)
All of the treatments have potential side effects, and no one treatment works for everyone